VICTORIA, BC , Nov. 7, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ: EPRX ) (TSX: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphereTM technology designed to optimize drug delivery for applications with significant unmet need, today announced its financial results for the third quarter of 2024.
All dollar values are in U.S. dollars unless stated otherwise.
"During the third quarter, we advanced our Phase 1b /2a RESOLVE trial for EP-104GI as a treatment for eosinophilic esophagitis, reporting further positive results from the fourth cohort and presenting the data at prominent medical conferences internationally," said Dr. James Helliwell , CEO of Eupraxia. "We also continued to raise the profile of our Phase 2b SPRINGBOARD osteoarthritis trial data through its publication in leading, peer-reviewed publication The Lancet Rheumatology.
Beyond our important clinical progress, subsequent to quarter end, we raised C$44.5 million and now anticipate that our EP-104GI program is funded through Phase 2 development. Finally, we also strengthened our senior management team and board during the reporting period, ensuring we have the strongest possible team in place to drive Eupraxia forward.
" Recent Operational and Financial Highlights On September 11, 2024 , the Company announced additional positive clinical data from its RESOLVE Phase 1b /2a trial which is evaluating the safety and efficacy of EP-104GI as a tr.